SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

by Linda Pudelko, Frank Jaehrling, Christof Reusch, Santiago Viteri, Christopher Stroh, Nina Linde, Michael P. Sanderson, Doreen Musch, Catherine Jorand Lebrun, Marina Keil, Christina Esdar, Andree Blaukat, Rafael Rosell, Karl Maria Schumacher, Niki Karachaliou
Published 2020-12-01